Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Currency in USD	2025
Operating Income	-166.76 Million
Income Before Tax	-183.7 Million
Income Tax Expense	-530 Thousand
Net Income	-183.17 Million
Eps	-3.68
Epsdiluted	-3.68
Weighted Average Shs Out	49.75 Million
Weighted Average Shs Out Dil	49.75 Million
Research And Development Expenses	183.28 Million
Selling General And Administrative Expenses	570.60 Million
Depreciation And Amortization	9.06 Million
Interest Expense	-15.93 Million
Interest Income	N/A
Net Interest Income	-6.56 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	591.02 Million
Ebitda	-160.17 Million
Source	edgar
Ebit	-177.15 Million

Axsome Therapeutics, Inc. Annual Reports (10-K)